Ainos

AIMD

Market cap $13.9M

Building the Olfactory Layer of Physical AI Highlighting Progress Across Semiconductor Manufacturing, Healthcare Infrastructure and Physical AI Applications HOUSTON, TX / ACCESS Newswire / June 8, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer in AI-powered scent digitization and Smell AI technologies, today released its 2026 Mid-Year Letter to Shareholders from Chairman, President and Chief Executive Officer Eddy Tsai. 2026 First Half Highlights Commercial Momentum Reported 499% year-over-year revenue growth during fiscal year 2025.

HOUSTON, TX / ACCESS Newswire / June 5, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today highlighted a recent report published by VASRO GmbH ("VASRO"), discussing the expansion of the Company's AI Nose platform into emergency department operations and the continued growth of its Smell ID data across diverse real-world environments. In the report, VASRO reviews Ainos' recently announced research program at one of Asia's leading academic medical centers, where AI Nose is being deployed within a live emergency department environment to evaluate environmental scent analysis for emergency department overcrowding early warning and respiratory infection risk analysis.

HOUSTON, TX / ACCESS Newswire / June 3, 2026 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today announced that Zacks Small-Cap Research ("Zacks SCR") has published a new article discussing Ainos' recently announced healthcare infrastructure study at National Taiwan University Hospital ("NTUH"). The article reviews Ainos' initiative to deploy AI Nose in a live emergency department environment and explores the potential role of Smell AI in environmental monitoring, healthcare infrastructure, and artificial intelligence applications.

AI Nose Expands from Semiconductor Facilities into Frontline Healthcare Infrastructure HOUSTON, TX / ACCESS Newswire / June 1, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today announced the launch of a research program at National Taiwan University Hospital ("NTUH"), one of Asia's leading academic medical centers, to deploy AI Nose inside a live emergency department environment for intelligent environmental monitoring, ER overcrowding early warning, and respiratory infection risk analysis. The program aims to expand Smell AI, powered by AI Nose, inside a real-world emergency department environment and expands market opportunities beyond semiconductor and industrial environments into frontline healthcare infrastructure.

HOUSTON, TX / ACCESS Newswire / May 20, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today highlighted a new research update published by VASRO GmbH discussing AI Nose, the Company's AI-powered scent digitization and Smell AI platform, and ongoing commercialization progress across semiconductor manufacturing, robotics integration, and healthcare infrastructure markets. The report notes that the Company is advancing initiatives intended to support potential second half 2026 revenue generation.

HOUSTON, TX / ACCESS Newswire / May 13, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced financial results for the first quarter ended March 31, 2026 and provided a business update on recent execution progress for AI Nose across semiconductors and healthcare infrastructure applications . During the first quarter of 2026, Ainos continued executing its commercialization priorities for AI Nose across industrial infrastructure environments while continuing to expand its Smell ID datasets and refine its Smell Language Model ("SLM") through deployment and pilot activities.

Updated classification reflects Ainos' transition toward AI-powered scent intelligence commercialization HOUSTON, TX / ACCESS Newswire / May 11, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it updated its Standard Industrial Classification ("SIC") code from SIC 2834 - Pharmaceutical Preparations to SIC 3577 - Computer Peripheral Equipment, NEC. We believe the updated classification reflects Ainos' operational evolution and commercialization focus on AI-powered sensing, industrial AI applications, and Smell AI technologies driven by AI Nose, the Company's proprietary AI-powered scent digitization platform.

2026 Identified as a Key Scale-Up Phase with Expanding Market Verticals and Accelerating Data Flywheel HOUSTON, TX / ACCESS Newswire / April 17, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) today highlighted the continued expansion of its Smell AI deployments, powered by AI Nose, across semiconductor, robotics, and healthcare infrastructure, highlighted by recent third-party research published by VASRO GmbH . The report underscores Smell AI's progression from isolated sensing applications to scalable multi-domain AI perception platform and identifies 2026 as a key scale-up year as Ainos moves toward deployment and repeatable revenue generation.

Expands AI Nose platform from industrial safety into clinical infrastructure HOUSTON, TX / ACCESS Newswire / April 8, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) today announced a partnership with MacKay Memorial Hospital and Topco Scientific Co., Ltd. to deploy its AI Nose technology across high-risk hospital environments.

Report highlights transition to deployment-driven growth, with visible semiconductor rollout and early customer-backed revenue Smell AI, powered by AI Nose, is emerging as a new AI perception layer, supported by accelerating commercialization and expanding industrial adoption HOUSTON, TX / ACCESS Newswire / April 1, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today highlighted findings from a research report published by VASRO GmbH, which points to accelerating commercial progress of "Smell AI" powered by AI Nose, and improving visibility into 2026 deployments. The report notes that Ainos has moved beyond early validation and is now entering a more execution-driven phase, supported by improving financial performance, customer commitments, and a clearer deployment roadmap.